extended release (SD+MD) [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2007-01-22 19:32 (7090 d 20:56 ago) – Posting: # 478
Views: 11,784

Dear ioanam!

❝ It was a single dose study(only in fasted conditions) and multi- dose study. In this study, the first period of the single dose study was followed by the first period of the steady - state study. The wash out period began after the last dose administered in the steady - state study. The second period was identical with the first one. Is correct this design for the study?


In this case the sponsor obviously tries to kill two birds with one stone :-D

Let's go into the datails - if I got it wright:
In steady state you measure for 24 hours, whereas in single dose your last sampling point is determined by the regulatory requirement to cover at least 80% of AUCinf (i.e., by the half life of the drug and the LLOQ of the assay).
Therefore the saturation phase for the multiple dose part may only start as early as the time point of the last expected concentration above LLOQ in any of the subjects (otherwise you may jeopardize accurate estimate of AUCinf in this subject).
Saturation up to steady state and the profile itself is pretty straightforward, but in order to get all drug cleared from the body (assuming accumulation) our washout to the second single dose period generally will be longer than for a 'conventional' single dose design.
Have you ever thought about the blood loss in such a 'design'?
What about statistics? Only if we close our eyes the comparisons for BE will come from 'periods 1&2' - because actually we have 4. BE will be calculated from 1&3 (single dose) and from 2&4 (steady state). We should incorporate this information in the model - and don't ask me about regulatory acceptance ;-)
What if one of the two parts fail to demonstrate BE? It will be impossible to 'split' your data...
We are also loosing time: in a multiple dose steady we dont need a washout phase at all; we may directly switch from one formulation to the other.

❝ I know that for extended - release formulations must be performed totally different studies (single dose and multi - dose studies) in different periods. Is this correct?


I would think so - see above ;-)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
162 visitors (0 registered, 162 guests [including 28 identified bots]).
Forum time: 17:29 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5